-
Duality Biologics completes US$90 million in Series B financing
Time of Update: 2021-07-06
A round of strategic investor WuXi Bioindustry The fund continues to support the company, and continues to provide the company with production process support that meets global quality standards to accelerate the research and development process .
-
AstraZeneca China and Boan Biotechnology reached a major strategic cooperation to help local anti-tumor biological drugs expand into county markets
Time of Update: 2021-07-06
The two parties will combine their respective advantages and resources in the field of market coverage and drug development to promote the expansion of anti-tumor biologics to the county market, and help more patients with non-small cell lung cancer and colorectal cancer benefit from China’s local anti-tumor biologics.
-
Sansheng Guojian completes Series C investment in Qide Pharmaceutical
Time of Update: 2021-07-06
At present, the pipeline of new drug research products of Qi Tak Pharmaceutical includes both a series of potential ADC varieties with known targets (best-in-class) and the first-in-class drug product with a new mechanism of action (first-in-class).
-
Financing continues to explode. Are Internet medical companies such as Kuaiyao "healthy"?
Time of Update: 2021-07-06
In 2014, Renhe Pharmaceuticals invested 5 million yuan in angel round investment to establish Dingdang Kuaiyao, starting with O2O drug delivery business .
The financial report shows that Ping An Good Doctor still has a huge loss of 949 million yuan in fiscal 2020 .
-
Livzon Pharmaceutical Fluvoxamine Maleate Tablets Passed Generic Drug Consistency Evaluation
Time of Update: 2021-07-06
Fluvoxamine maleate tablets passed generic drugs with consistent quality and efficacy.
As of the disclosure date of this announcement, the cumulative direct R&D expenses for the consistency evaluation of fluvoxamine maleate tablets have been approximately RMB 7,073,500 .
-
The highest proportion is 1210.56%, and the net profit of listed pharmaceutical companies is "moisture" Top 10!
Time of Update: 2021-07-06
52% year-on-year to 43 million yuan, and the net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses increased by 92.
billion, during the non-recurring gains and losses 083 million yuan, net profit of 191.
-
Kangsino Biological and other companies increase the capital of Shanghai Pharmaceutical Kangsino by about 1.1 billion yuan
Time of Update: 2021-07-06
On May 17, Cansino Biopharmaceuticals issued an announcement stating that Cansino Bio and Shanghai Sanwei Biotech agreed to increase the capital of Shanghai Pharmaceutical Kangsino Biopharmaceutical Co.
89 million, respectively, to increase the registered capital of Shanghai Pharmaceutical Kangsino Biopharmaceutical Co.
-
Mengke Pharmaceutical and Biosaito reached a strategic cooperation on jointly promoting innovative anti-infective biological drugs
Time of Update: 2021-07-06
This cooperation will be based on the fully human antibody mice (RenMab®, RenLite®, RenNano®) based on Biocytogen’s independent intellectual property rights, and the development of high-efficiency antibodies and a complete preclinical pharmacology and drug efficacy research platform.
-
Neusoft Medical, the largest domestic CT manufacturer, renews its IPO, and its profits rely heavily on subsidies for "blood transfusion"
Time of Update: 2021-07-06
Reporter | Yuan YimingEdit | Xie Xin The Hong Kong Stock Exchange disclosed on May 31 that Neusoft Medical, a subsidiary of Neusoft Group, had submitted a listing application to the Hong Kong Stock Exchange, and CICC and Goldman Sachs were joint sponsors .
The previous prospectus showed that Neusoft Medical’s net profit fluctuated greatly.
-
The performance of Lianhua Qingwen Capsule has doubled, but Yiling Pharmaceuticals wants to lay off medical representatives?
Time of Update: 2021-07-06
According to its 2018 and 2017 annual reports, the average year-on-year increase in operating income was below 20%, and the average year-on-year increase in net profit was below 10% .
. According to the 2020 annual report of Yiling Pharmaceutical, in the first half of 2020, Lianhua Qingwen series products accounted for 37.
-
Takeda China and China hereditary angioedema care center Swift held a popular science pop-up exhibition
Time of Update: 2021-07-06
Wu Zhongyi, Head of Rare Genetics and Metabolism Business of Takeda China, and Luo Fang, Swift Representative of China Hereditary Angioedema Care Center Madam, Professor Li Dingguo, Chairman of the Shanghai Rare Disease Prevention and Treatment Foundation, Professor Guo Yinshi, Director of the Department of Allergy, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Dr.
-
The first generic drug "Axitinib" is about to be approved for listing
Time of Update: 2021-07-06
Recently, the official website of the State Food and Drug Administration showed that Shandong New Era's application for axitinib generic drug listing in category 4 is in the “under review” stage and will soon be approved by the NMPA.
-
Loss of 700 million a year!
Time of Update: 2021-07-06
Focus on small molecule precision tumor therapy and immuno-oncology therapy Layout of 14 innovative product pipelines, 4 of which have entered the clinical stage Heyu Biology is a R&D-driven, clinical-stage biomedical company, focusing on the two core areas of today's cancer treatment-small molecule tumor targeting and tumor immune drug research and development .
-
Cochlear releases the latest annual reliability report
Time of Update: 2021-07-06
Authoritative and objective, Cochlear continues to demonstrate high product reliability The reliability report released by Cochlear follows the industry's most authoritative and strict international statistical standard for cochlear implant reliability: implants use "European Consensus and International Classification Standards" (referred to as European standards), and sound processors use ANSI/AAMI CI86 (Referred to as American Standard) .
-
Lepu Medical intends to list Xintai Technology on the main board of the Hong Kong Stock Exchange
Time of Update: 2021-07-06
The announcement disclosed that Xintai Technology is mainly engaged in the research and development, production and commercialization of medical devices for structural heart disease intervention .
-
Zhifei Bio: Mycobacterium vaccae for injection is approved for marketing
Time of Update: 2021-07-06
On June 16, Zhifei Biological announced that the company's independent product Mycobacterium vaccae for injection had obtained the drug registration certificate issued by the State Food and Drug Admi
-
Olin Biotech officially listed on the Science and Technology Innovation Board
Time of Update: 2021-07-06
This morning, Olin Biologics was officially listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange .
It is reported that the company's IPO adopted the fifth set of listing standards on the Science and Technology Innovation Board, the sponsor (lead underwriter) is Yingda Securities, and the issue price is 9.
-
Medical Federation and Panorama Medicine reached a strategic cooperation to strengthen the medical "cloudification" layout
Time of Update: 2021-07-06
This time Panorama cooperates with the Medical Federation, and hopes that through the channel layout capabilities of both parties, more patients can enjoy efficient, high-quality and convenient image diagnosis services .
-
Lunsheng Pharmaceutical Announces Positive Preliminary Results of CABP's Phase 3 Lefarmoreline Trial
Time of Update: 2021-07-06
Lunsheng Pharmaceutical, a Chinese biopharmaceutical company that focuses on innovative biomedical research and development in China, and Nabriva Therapeutics, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infectives to treat severe infections, today announced that Lunsheng has acquired bacterial pneumonia in the community ( The Phase 3 bridging trial of Lefamorin in Chinese adult patients of CABP has achieved positive preliminary results .
-
Sihuan Medicine Degu Aspart Double Insulin Injection was approved for clinical use
Time of Update: 2021-07-06
On June 7, the official website of CDE showed that the diabetes drug Degu aspartic insulin injection developed by Jilin Huisheng Biological, a subsidiary of Sihuan Pharmaceutical, was approved for clinical use.
It is the first clinically approved biosimilar drug in China.
